Skip to main content

Table 2 Central and peripheral hemodynamic data during pulse wave analysis in patients with and without metabolic syndrome

From: Association of HIV-infection, antiretroviral treatment and metabolic syndrome with large artery stiffness: a cross-sectional study

 

No Metabolic Syndrome

Metabolic Syndrome

Variable

Controls

HIV-1 untreated

HIV-1 cART

Controls

HIV-1 untreated

HIV-1 cART

(n = 39)

(n = 32)

(n = 42)

(n = 10)

(n = 16)

(n = 12)

Central systolic BP

113 ± 12

116 ± 10

114 ± 10

126 ± 7c

120 ± 13

110 ± 11b

Peripheral systolic BP

123 ± 13a

127 ± 11a

124 ± 11a

135 ± 7ac

129 ± 11a

120 ± 13a

Central diastolic BP

75 ± 7

78 ± 6

78 ± 8

81 ± 3c

78 ± 6

74 ± 7b

Peripheral diastolic BP

74 ± 7a

77 ± 6a

76 ± 8a

79 ± 3ac

72 ± 7a

72 ± 7ab

Central MAP

87 ± 8

91 ± 7

90 ± 9

96 ± 3c

92 ± 7

86 ± 8b

Peripheral MAP

90 ± 8a

93 ± 7a

92 ± 8a

98 ± 2ac

94 ± 7a

87 ± 8bc

Central PP

38 ± 9

38 ± 8

36 ± 7

45 ± 8c

41 ± 9

36 ± 8

Peripheral PP

49 ± 10a

50 ± 10a

47 ± 7a

56 ± 9a

52 ± 9a

45 ± 8ab

PP amplification (ratio)

1.33 ± 0.17

1.33 ± 0.14

1.32 ± 0.13

1.24 ± 0.12

1.29 ± 0.12

1.25 ± 0.19

Heart rate (beats/min)

67 ± 11

76 ± 10b

74 ± 11b

66 ± 7

74 ± 6

78 ± 13b

  1. Values (mmHg) are means ± SD. cART combined antiretroviral therapy, BP blood pressure, MAP mean arterial pressure, PP pulse pressure, aP < 0.001 for within-group central variable, bP < 0.01 versus within-group controls, cP < 0.001 vs. no metabolic syndrome controls